Rhythm Pharmaceuticals, Inc.
RYTM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001649904
In the last 90 days, Rhythm Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 307 institutions reported holding it in 13F filings for Q2 2026, worth $8.55B in total; Duquesne Family Office is the only superinvestor holding it.
Key figures
- Market capClose on Nov 9, 2026
- $7.90B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $28.8M in total
- 6
- 13F holdersQ2 2026, +23 vs. previous quarter
- 307
- 13F valueReported value at the end of Q2 2026
- $8.55B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $189.8M
- +45.8% year over year
- Net income, FY2025
- -$196.5M
- No comparable prior period
- Free cash flow, FY2025
- -$116.6M
- No comparable prior period
- Revenue, Q3 FY2026
- $92.1M
- +79.6% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $196.5M (103.6% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 11.0M
- Shares sold short
- Change
- +235.8K
- +2.2% vs. previous
- Days to cover
- 13.48
- At average daily volume
Superinvestors holding RYTM, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Rhythm Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.5%
Rhythm Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 203,618
- Value
- $22.6M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Rhythm Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 (view filing)7:37 PM ET | Sep 14 | Same day | Meeker David PPresident and CEO | SSale | −50.0K | $102.67 | −$5.13M | −17.3%239.3K after | 5 lots10b5-1 |
| Sep 1, 2026 (view filing)4:22 PM ET | Aug 31 | 1 day | Smith Hunter CChief Financial Officer | SSale | −62.8K | $105.46 | −$6.62M | −35.5%114.0K after | 3 lots10b5-1 |
| Aug 17, 2026 (view filing)6:00 PM ET | Aug 13 | 4 days | Shulman JosephChief Technical Officer | SSale | −5.08K | $119.75 | −$608.2K | −24.2%15.9K after | 10b5-1 |
| Aug 17, 2026 (view filing)5:57 PM ET | Aug 13 | 4 days | Garfield AlastairChief Scientific Officer | SSale | −7.76K | $117.57 | −$912.7K | −77.2%2.29K after | 4 lots10b5-1 |
| Aug 14, 2026 (view filing)7:04 PM ET | Aug 13 | 1 day | Chien JenniferEVP, Head of North America | SSale | −75.8K | $117.38 | −$8.90M | −100.0%0 after | 10b5-1 |
| Aug 14, 2026 (view filing)7:01 PM ET | Aug 12 | 2 days | Mazabraud YannEVP, Head of International | SSale | −57.0K | $116.15 | −$6.62M | −50.6%55.7K after | 6 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Tetrault Lynn A.Director | SSale | −37.0K | $100.32 | −$3.71M | −84.1%7.00K after | 10b5-1 |
| May 19, 2026 (view filing) | May 15 | 4 days | German Christopher PaulCorporate Controller & CAO | SSale | −4.64K | $92.21 | −$428.1K | −100.0%0 after | |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | German Christopher PaulCorporate Controller & CAO | SSale | −5.61K | $89.56 | −$502.8K | −97.2%160 after | |
| Feb 19, 2026 (view filing) | Feb 17-19 | 2 days | Smith Hunter CChief Financial Officer | SSale | −7.95K | $101.31 | −$805.8K | −6.7%110.5K after | 9 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 307 holdersThe largest institutional positions in Rhythm Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 6,666,837 | $740.2M | 6.43% | 00.0% | Unchanged |
| BlackRock, Inc. | 6,156,902 | $683.6M | 0.01% | −80,249−1.3% | Reduced |
| Baker Bros. Advisors LP | 5,604,483 | $622.3M | 3.12% | 00.0% | Unchanged |
| Primecap Management Co | 3,168,853 | $351.8M | 0.21% | −248,656−7.3% | Reduced |
| Vanguard Portfolio Management LLC | 3,136,895 | $348.3M | 0.02% | +96,177+3.2% | Added |
| Vanguard Capital Management LLC | 3,005,977 | $333.8M | 0.01% | +38,152+1.3% | Added |
| JPMorgan Chase & Co | 2,652,746 | $292.2M | 0.02% | +1,099,102+70.7% | Added |
| Perceptive Advisors LLC | 2,586,295 | $287.2M | 4.46% | +212,500+9.0% | Added |
| State Street Corp | 2,573,529 | $285.7M | 0.01% | +301,678+13.3% | Added |
| Price T Rowe Associates Inc | 2,566,171 | $284.9M | 0.03% | +911,295+55.1% | Added |
Holders of 5% or more of RYTM
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Rhythm Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13G/A | 9.90%6.67M shares | +1.20 ppfrom 8.70% | Feb 16, 20217 filings | Feb 17, 2026 | SEC |
| Baker Bros. Advisors LP | 13G/A | 8.90%5.60M shares | – | Feb 16, 20216 filings | May 15, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 6.90%4.36M shares | – | Apr 24, 20251 filing | Apr 24, 2025 | SEC |
| Primecap Management Co | 13G/A | 5.21%3.48M shares | −1.21 ppfrom 6.42% | Feb 12, 202111 filings | Feb 12, 2026 | SEC |
| JPMorgan Chase & Co | 13G | 5.10%3.56M shares | New | Oct 13, 20261 filing | Oct 13, 2026 | SEC |